Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists [3]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 4, 2005, Pages 797-798

  Tjernberg, P ^a   Van Der Heijden, J F ^b   Eikenboom, J C J ^a   Reitsma, P H ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; GENOMIC DNA; HEMOGLOBIN; PHENPROCOUMON; POLYMER; THROMBOMODULIN; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; VITAMIN K GROUP;

BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; GENETIC RISK; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; MUSCLE BLEEDING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSEUDOGENE; VENOUS THROMBOEMBOLISM; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG ANTAGONISM; EVALUATION; EXON; GENETICS; HETEROZYGOTE; RISK; RISK FACTOR;

ANTICOAGULANTS; CASE-CONTROL STUDIES; CLINICAL TRIALS; EVALUATION STUDIES; EXONS; HEMORRHAGE; HETEROZYGOTE; HUMANS; POLYMORPHISM, GENETIC; RISK; RISK FACTORS; VITAMIN K; VON WILLEBRAND FACTOR;

EID: 23044490264     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01243.x     Document Type: Letter

References (8)

1. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.
2. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
3. van der Heijden JF, Rekke B, Hutten BA, van der Meer FJ, Remkes MG, Vermeulen M, Buller HR, Reitsma PH. Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. J Thromb Haemost 2004; 2: 1104-9.
4. Jansson JH, Boman K, Brannstrom M, Nilsson TK. High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. Circulation 1997; 96: 2938-43.
5. Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS-13. Blood 2004; 103: 941-7.
6. O'Brien LA, James PD, Othman M, Berber E, Cameron C, Notley CR, Hegadorn CA, Sutherland JJ, Hough C, Rivard GE, O'Shaunessey D, Lillicrap D. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003; 102: 549-57.
7. Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-27.
8. Mehta CR, Patel NR, Gray R. Computing an exact confidence interval for the common odds ratio in several 2x2 contingency tables. J Am Stat Assoc 1985; 80: 969-73.